Design, Development and In vitro Characterization of Pioglitazone Loaded Mucoadhesive Buccal Devices

Authors

  • Raj Kaur Malik Research Scholar, Department of Pharmaceutics, School of Pharmacy, Bharat Institute of Technology, Meerut-250103 (U.P.)
  • Prashant Malik Research Scholar, Department of Pharmaceutics, School of Pharmacy, Bharat Institute of Technology, Meerut-250103 (U.P.)
  • Neha Gulati Research Scholar, Department of Pharmaceutics, School of Pharmacy, Bharat Institute of Technology, Meerut-250103 (U.P.)
  • Upendra Nagaich Research Scholar, Department of Pharmaceutics, School of Pharmacy, Bharat Institute of Technology, Meerut-250103 (U.P.)

Keywords:

Eudragit, HPMC K4M, Mucoadhesion, Solvent casting method.

Abstract

Aim: The mucoadhesive buccal patches were developed and evaluated for systemic administration of Pioglitazone in the oral cavity. Pioglitazone belongs to a novel class of oral antidiabetic drugs known as Thiazolidinediones.

Materials and Methods: The mucoadhesive buccal patches of Pioglitazone was formulated using Eudragit RS100 and HPMC K4M (mucoadhesive polymer) and were prepared by solvent casting method. Different patch formulations were evaluated for its physical parameters like thickness uniformity, swelling index, surface pH, uniformity of weight, folding endurance, mucoadhesive strength and in vitro parameters like drug content uniformity and drug release studies, and ex vivo parameters like mucoadhesion time.

Results: Data for the parameters was found to be: thickness uniformity (0.27±0.45mm); uniformity of weight (40.81±0.66 mg), surface pH (6.5), folding endurance (>300), drug content uniformity (98.58±2.05%), swelling index (131±0.79%), mucoadhesive strength (38.20±1.75), in vitro drug release studies (95.18±1.98%) and ex vivo mucoadhesion, time of optimized formulation (4±1.26 h). The data was also fitted to different kinetic models to illustrate its anomalous (non-fickian) diffusion.

Conclusions: The result revealed that Pioglitazone loaded buccal patches was most suitable mode of drug delivery for promising therapeutic action. Buccal patches of Pioglitazone can prove to be potential pharmaceutical dosage form for sustaining the drug release and reducing the dose frequency.

Downloads

Download data is not yet available.

References

Alagusundaram M, Chetty CM, Dhachinamoorthi D. Development and evaluation of novel-trans-buccoadhesive films of famotidine. J Adv Pharm Tech Res. 2011;2(1):17-23.

Miller NS, Johnston TP. The use of mucoadhesive polymers in buccal drug delivery. Adv Drug Deliver Rev. 2005;57:1666-91.

Lalla JK, Gurnancy RA. Polymers for mucosal Delivery-Swelling and Mucoadhesive Evaluation. Indian Drugs. 2002;5:39.

Singh A, Patel P, Bukka R, Patel J. Preparation and evaluation of buccal formulation for triamcinolone. Int J Curr Pharm Res. 2011;3(3):74-80.

Pathan AM, Channawar MA, Bakde BV, Chandewar AV. Development and in vitro evaluation of salbutamol sulphate mucoadhesive buccal patches. Int J Pharm Pharm Sci. 2011;3(2):39-44.

Panda S, Acharya S, Gandhi J, Patel N. Development and Characterization of Mucoadhesive patches of Glimepiride for buccal administration. J Pharm Sci Biosci Res. 2011;1(2):102-7.

Nafrialdi. Efficacy and safety of pioglitazone in type 2 diabetes mellitus: A postmarketing observational study. Acta Medica Indonesiana. 2012;44(1):28-34.

Suganya S, Bright A, Devi TSR. Studies on linearty and assay using RP-HPLC and UV-Visible spectroscopy for the drugs oxcarbazepine and pioglitazone before and after expiry period. Int J Pharm Sci Res. 2012;3(6):1731-4.

USP 30, NF 25, 2007, pp. 2901.

Rao NR, Kandhadi SR, Swapna D, Konasree SD, Enugala S. Formulation and evaluation of rapidly dissolving buccal patches. Int J Pharm Bio Sci. 2011;1(3):145-59.

Patel RS, Poddar SS. Development and Characterization of Mucoadhesive Buccal Patches of Salbutamol Sulphate. Current Drug Delivery. 2009;6:140-4.

Khanna R, Agarwal SP, Ahuja A. Preparation and evaluation of mucoadhesive buccal films of clotrimazole for oral Candida infections. Indian J Pharm Sci. 1997;59:299-305.

Kumar BV, Kumar AA, Sudheer B, Kumar SK, Rao SV, Kirtinidhi K, et al. Formulation design, in vitro evaluation and stability studies on mucoadhesive buccal films of anti-anginal calcium channel blocker. J Applied Pharma Sci. 2011;1(6):136-42.

Ajeet, Chaudhary R, Gupta A, Ram SK. Formulation, Development of Mucoadhesive Placebo Buccal Patches: Physical Characterization. Indian Journal of Novel Drug Delivery. 2011;3(3):226-9.

Jafar M, Ali S. Development and evaluation of Meloxicam solid dispersion loaded buccal patches. J Applied Pharm Sci. 2011;1(3):77-82.

Koland M, Charyulu RN, Prabhu P. Mucoadhesive films of Losartan Potassium for buccal delivery: Design and Characterization. Indian J Pharm Educ Res. 2010;44(4):315-23.

Patil DA, Patil GB, Deshmukh PK, Belgamwar VS, Fursule RA. Chitosan coated mucoadhesive multiparticulate drug delivery system for gliclazide. Asia J Pharma Clini Resea. 2009;2(2):18-25.

Singhal P, Jadoun GS, Sinha M, Saraf SA. Formulation and evaluation of buccal patches of terbutaline sulphate. Int J Res Pharm Sci. 2010;1(4):440-9.

Rao NGR, Patel K, Reddy MS, Kistayya C. Development and evaluation of ropinirole mucoadhesive patches for buccal drug delivery. Drug Invention Today. 2012;4(10):519-26.

Dash S, Murthy PN, Nath L, Chowdhury P. Kinetic modeling on drug release from controlled drug delivery systems. Acta Pol Pharm. 2010;67(3):217-23.

Downloads

Published

2014-06-20

How to Cite

1.
Kaur Malik R, Malik P, Gulati N, Nagaich U. Design, Development and In vitro Characterization of Pioglitazone Loaded Mucoadhesive Buccal Devices. Ars Pharm [Internet]. 2014 Jun. 20 [cited 2024 Jul. 22];55(2):25-31. Available from: https://revistaseug.ugr.es/index.php/ars/article/view/4491

Issue

Vol. 55 No. 2 (2014)

Section

Original Articles

License

The articles, which are published in this journal, are subject to the following terms in relation to the rights of patrimonial or exploitation:

  1. The authors will keep their copyright and guarantee to the journal the right of first publication of their work, which will be distributed with a Creative Commons BY-NC-SA 4.0 license that allows third parties to reuse the work whenever its author, quote the original source and do not make commercial use of it.

b. The authors may adopt other non-exclusive licensing agreements for the distribution of the published version of the work (e.g., deposit it in an institutional telematic file or publish it in a monographic volume) provided that the original source of its publication is indicated.

c. Authors are allowed and advised to disseminate their work through the Internet (e.g. in institutional repositories or on their website) before and during the submission process, which can produce interesting exchanges and increase citations of the published work. (See The effect of open access).